These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 12857602)

  • 1. Role of interleukin-15 and interleukin-18 in the secretion of sIL-6R and sgp130 by human neutrophils.
    Jablonska E; Marcinczyk M
    Mediators Inflamm; 2003 Jun; 12(3):179-83. PubMed ID: 12857602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of soluble gp130 in the tumour necrosis factor-alpha expression and its production by peripheral blood mononuclear cells.
    Jablonskaca E; Puzewska W; Marcinczyk M; Jablonski J
    Mediators Inflamm; 2003 Dec; 12(6):355-9. PubMed ID: 14668095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of soluble interleukin-6 receptor alpha and interleukin-6 secreted by polymorphonuclear leukocytes on tumor necrosis factor-alpha expression and its production by peripheral blood mononuclear cells.
    Jablonska E
    Mediators Inflamm; 2002 Oct; 11(5):325-8. PubMed ID: 12467526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
    Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
    J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of IL-18 on IL-1beta and sIL-1RII production by human neutrophils.
    Jabłońska E; Izycka A; Wawrusiewicz N
    Arch Immunol Ther Exp (Warsz); 2002; 50(2):139-41. PubMed ID: 12022703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of IL-18 on the release of IL-6 and its soluble receptors: sIL-6Ralpha and sgp130 by human neutrophils.
    Jablonska E; Jablonski J
    Immunol Invest; 2002; 31(3-4):159-67. PubMed ID: 12472176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of IL-15 on the secretion of IL-1beta, IL-1Ra and sIL-1RII by PMN from cancer patients.
    Jablonska E; Piotrowski L; Kiluk M; Jablonski J; Grabowska Z; Markiewicz W
    Cytokine; 2001 Dec; 16(5):173-7. PubMed ID: 11814312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of serum soluble interleukin-6 receptor and soluble gp130 levels in patient with pregnancy induced hypertension and its significance].
    Li Y; Wang Y; Qi L
    Zhonghua Fu Chan Ke Za Zhi; 2001 Jan; 36(1):18-9. PubMed ID: 11778537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum.
    Gaillard J; Pugnière M; Tresca J; Mani J; Klein B; Brochier J
    Eur Cytokine Netw; 1999 Sep; 10(3):337-44. PubMed ID: 10477390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between TNF-alpha, IL-6 and their soluble receptors in the cultures of human PMN, PBMC and WBC.
    Jabłońska E
    Rocz Akad Med Bialymst; 2001; 46():77-86. PubMed ID: 11780583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR2 expression in relation to IL-6 and IL-1beta and their natural regulators production by PMN and PBMC in patients with Lyme disease.
    Jablonska E; Marcinczyk M
    Mediators Inflamm; 2006; 2006(1):32071. PubMed ID: 16864901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-4 production by human polymorphonuclear neutrophils.
    Brandt E; Woerly G; Younes AB; Loiseau S; Capron M
    J Leukoc Biol; 2000 Jul; 68(1):125-30. PubMed ID: 10914499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble gp130 is up-regulated in the implantation window and shows altered secretion in patients with primary unexplained infertility.
    Sherwin JR; Smith SK; Wilson A; Sharkey AM
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3953-60. PubMed ID: 12161539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases.
    Michalopoulou M; Nikolaou C; Tavernarakis A; Alexandri NM; Rentzos M; Chatzipanagiotou S; Cambouri C; Vassilopoulos D
    Immunol Lett; 2004 Jul; 94(3):183-9. PubMed ID: 15275965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
    Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
    J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered pulmonary interleukin-6 signaling in preterm infants developing bronchopulmonary dysplasia.
    von Bismarck P; Claass A; Schickor C; Krause MF; Rose-John S
    Exp Lung Res; 2008 Dec; 34(10):694-706. PubMed ID: 19085566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of IL-6/sIL-6R on ex vivo expansion of human cord blood derived CD34+ cells].
    Feng JF; Zhuang M; Zhu LJ; Sheng ZL; Zhu YQ; Li CP
    Ai Zheng; 2004 Jun; 23(6):715-8. PubMed ID: 15191679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-15 in the culture supernatants of PMN and PBMC and the serum of patients with Lyme disease.
    Jabłońska E; Marcińczyk M; Talarek Ł; Pancewicz S; Hermanowska-Szpakowicz T; Jabłoński J
    Rocz Akad Med Bialymst; 2003; 48():78-81. PubMed ID: 14737947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.
    Desgeorges A; Gabay C; Silacci P; Novick D; Roux-Lombard P; Grau G; Dayer JM; Vischer T; Guerne PA
    J Rheumatol; 1997 Aug; 24(8):1510-6. PubMed ID: 9263143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Examination and evaluation of sIL-6R, sgp130 in serum in patients with chronic hepatopathy].
    Shang J; Xu Y; Zhang H
    Zhonghua Gan Zang Bing Za Zhi; 2000 Apr; 8(2):87-8. PubMed ID: 10861111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.